This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)
NattoPharma ASA is pleased to announce that our patent CA 2347387 "Vitamin K2 Containing Food product/Vitamine K2 Contenant Un Produit Alimentaire" has been approved and issued in Canada by the Canadian Intellectual Property Office (CIPO). This will strengthen NattoPharma's IPR and commercial future platform in Canada significantly. The patent will give NattoPharma a broad coverage on the use of menaquinones (vitamin K2) in the preparation of a food product (including dietary supplement) for maintaining, optimizing, strengthening or promoting cardiovascular health.
"The approval and issue of the patent represents a milestone for NattoPharma and our partners. This will strengthen NattoPharma's global IPR-platform and contribute to NattoPharma's competitive advantage in Canada and the ability to support our customers and partner Quadra Chemicals Ltd. in the marketing of MenaQ7 within the food supplement market as well as the functional food market" says Peter Carlsson, CEO of NattoPharma. Further, Peter Carlsson states "that this will also be of valuable support in the ongoing commercialization of our product MenaQ7® in the region".
About NattoPharma ASA
NattoPharma ASA, Norway is the exclusive international supplier of MenaQ7, the natural vitamin K2. NattoPharma has entered into a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the exciting marketplace for functional food and health food supplements.
For more information, please visit www.nattopharma.com
MenaQ7 provides natural vitamin K2 as a fermentation extract whereby vitamin K2 is manufactured using bascillus subtilis natto. This process has the capacity of producing the highly pure and bio-available form of vitamin K2, menaquinone-7 (MK-7). MenaQ7 is the best documented, commercially available natural vitamin K2 with guaranteed actives and stability, clinical substantiation and international patents granted and pending.
For more information on the health benefits of MenaQ7, please visit www.menaq7.com
For more information, please contact:
CEO Peter Carlsson
+47 950 499 06